Findings showed 46.4% of patients treated with upadacitinib 15 mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

智通财经APP获悉，艾伯维(ABBV.US)周五宣布上调2025年盈利预期，得益于其新型免疫药物Skyrizi和Rinvoq的强劲销售表现，公司第一季度业绩超出华尔街预期。

RINVOQ/RINVOQ LQ is a prescription medicine used to treat: Children 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) when 1 or more medicines called TNF ...

AbbVie announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

(RTTNews) - AbbVie (ABBV) Tuesday said the U.S. Food and Drug Administration (FDA) has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease ...